Ozmosi | Atorvastatin Drug Profile

Product Description

Atorvastatin is used together with diet, weight loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. Atorvastatin is also used to decrease the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol ('bad cholesterol') and triglycerides in the blood and to increase the amount of high-density lipoprotein (HDL) cholesterol ('good cholesterol') in the blood.

Mechanisms of Action: HMG-CoA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atorvastatin

Countries in Clinic: Australia, Canada, China, Denmark, Estonia, Finland, Korea, Norway, Portugal, South Korea, United States

Active Clinical Trial Count: 28

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Kidney Cancer|Ovarian Cancer

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06948747	D7260C00017	P1	Completed	Obesity\|Type 2 Diabetes	2025-10-03	50%	2025-10-11
CTR20244613	CTR20244613	P1	Completed	Healthy Volunteers\|General Diabetes	2025-06-09		2025-06-22	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT06567327	C3421086	P1	Completed	Obesity\|Overweight	2025-03-16	50%	2025-08-07
NCT05342974	NCT05342974	P1	Completed	Pregnancy Outcomes	2023-12-31		2025-03-22	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
2019-001982-34	2019-001982-34	P2	Active, not recruiting	Breast Cancer\|Prostate Cancer\|Kidney Cancer\|Ovarian Cancer	2025-06-15
2025-521452-30-01	2025-521452-30-01	P3	Not yet recruiting	Brain Infarction	2028-09-30
NCT06974084	IMPACT-LC	P3	Not yet recruiting	Post Acute COVID-19 Syndrome	2026-02-01		2025-05-16	Primary Endpoints\|Treatments
NCT04026230	ESTO2	P3	Recruiting	Prostate Cancer	2025-12-31		2022-10-22	Primary Endpoints\|Start Date\|Treatments
NCT05930028	BR-FAEC-CT-301	P3	Completed	Hypercholesterolemia\|Hypertension	2024-09-05	7%	2024-10-19	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT05970679	DW1125-301	P3	Completed	Dyslipidemia\|Hypercholesterolemia	2023-04-13		2023-08-02
ACTRN12620000198921p	BCHCP	P3	Not yet recruiting	Acute Pain\|Obesity	2021-10-31
CTR20251534	CTR20251534	P1	Completed	Hyperlipidemia\|Hypercholesterolemia	2025-10-25		2025-12-06
NCT05815680	CIBI362D101	P1	Completed	Overweight	2023-08-18	4%	2025-08-27	Primary Endpoints\|Treatments
2024-515404-39-00	2024-515404-39-00	P3	Active, not recruiting	Breast Cancer	2045-01-01		2025-05-02	Treatments
NCT07265466	JP-1366-106	P1	Recruiting	Healthy Volunteers	2026-03-30	88%	2025-12-05	Primary Endpoints
NCT07268625	DSE-BMP-0003-CIS-MA	P1	Not yet recruiting	Unknown	2026-03-03	88%	2025-12-11	Primary Endpoints\|Treatments
NCT07235189	DSE-BMP-0001-CIS-MA	P1	Recruiting	Healthy Volunteers	2026-01-21		2025-11-20	Primary Endpoints\|Treatments
NCT06140095	PSM1A	P1	Not yet recruiting	Healthy Volunteers	2025-12-01	23%	2023-11-19	Primary Endpoints\|Treatments
NCT06723691	HRS9531-107	P1	Completed	Type 2 Diabetes	2025-06-09	88%	2025-06-24
NCT06601517	HDM1002-106	P1	Not yet recruiting	Overweight	2025-02-01	2%	2024-09-24	Primary Endpoints
NCT06289504	NN9838-4694	P1	Completed	Obesity	2024-10-16	12%	2025-01-11	Patient Enrollment\|Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Trial Status
NCT06293742	EC0007	P1	Completed	Type 2 Diabetes	2024-04-15	12%	2024-07-23
NCT06699355	MK-0616-024	P1	Completed	Healthy Volunteers	2023-12-29		2024-11-22	Primary Endpoints\|Treatments
CTR20233333	CTR20233333	P1	Completed	Hypercholesterolemia	2023-12-27		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
NCT06081166	TA-8995-11	P1	Completed	Healthy Volunteers	2023-12-02	69%	2025-02-07	Primary Endpoints\|Treatments

Recent News Events

Date	Type	Title
11/27/2025	News Article	Inhaled Therapy in Respiratory Disease Market to Grow USD 16.22 Billion by 2034
11/26/2025	News Article	Angel Accelerates DAVID Theatrical Rollout Across 43 International Markets
11/19/2025	News Article	Adm. Craig Faller (Ret.) and Adele Gulfo Elected to Battelle Board of Directors
11/19/2025	News Article	Amy Rudolph, PhD, Joins Thryv Therapeutics' Board of Directors to Support Portfolio Progression into Heart Failure

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Atorvastatin

Alternative Names: atorvastatin, lipitor, sortis, atorvastatina, tulip, lipilou, lipinon, artovastatin, atorvastatine, liptruzet, lypqozet Clinical Status: Inactive Latest Update: 2025-12-08 Latest Update Note: Clinical Trial Update